drugset

drugset / Trial / NCT01941641

Colon Neoadjuvant FOLFOXIRI Study

NCT01941641 ↗

Phase 2 Active not recruiting 40 enrolled Chinese University of Hong Kong

NaSingle-groupOpen-labelTreatment

Summary

Objective tumour response rate to FOLFOXIRI to pre-operative therapy.

Timeline

Start: 2013-10-09
Primary completion: 2026-12-31
Completion: 2027-12-31

Publications

Lui RN, Chu S, Ng DCK, Li L, Cho CCM, Hung EHY, Wong KH, Mo FKF, Wong ECH, Hui CWC, Lam DCM, Suen J, Kang W, Ho WM, Futaba K, Hon SSF, Yan K, Ng SSM, Ma BBY. Multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent chemoradiotherapy in Chinese patients with high-risk rectal cancer. Oncologist. 2026 May 8;31(6):oyag162. doi: 10.1093/oncolo/oyag162.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	—	—

Indications